ADOPTIVE IMMUNOTHERAPY OF EXPERIMENTAL OVARIAN-CANCER USING ACTIVATEDHUMAN MONOCYTES AND THE HUMAN MONOCLONAL-ANTIBODY, ANTI-14C1

We have examined the ability of the ovarian cancer cell-line OWmM1 to grow intraperitoneally in athymic ('nude') mice. The cell-line was tum origenic and metastatic in a manner that paralleled the human disease; the metastatic nodules implanted onto the peritoneal surface, the dia phragm and the mesentery. The resulting tumour formed a clear ascitic fluid and peritoneal carcinomatosis. Adoptive transfer of activated hu man monocytes to the peritoneal cavity of tumour-bearing animals showe d no increase in survival, while antibody alone produced a modest surv ival benefit (2-4 days). Administration of the human monoclonal antibo dy anti-14C1 and monocyte therapy together increased the benefit furth er and resulted in approximately 30% of the animals surviving until th e end of the experiment (100 days).